Ona Therapeutics announced securing €30M from Sabadell Asabys, Alta Life Sciences, Ysios Capital, FundPlus and BPI France

Spain Investments 16 June 2020
Share on FacebookShare on Twitter

Ona Therapeutics, a Barcelona, Spain-based biotechnology company, announced completing a capital investment round totalling € 30 million ($34M).

The money was provided by a range of Spanish and international investors, including Sabadell Asabys, Alta Life Sciences, Ysios Capital, the Belgian fund FundPlus and the French BPI France.

With this capital injection, the biotechnology company covers the financial needs to complete the preclinical development and carry out the first clinical studies with its medicine to treat patients with metastatic cancer. The first clinical studies are expected to start in 2023.

Ona Therapeutics, led by CEO Valerie Vanhooren, was founded in 2019 by IRB Barcelona, ​​ICREA and researchers Salvador Aznar-Benitah and Valerie Vanhooren based on research published in January 2017 in Naturepor Aznar Benitah. Headquartered at the Barcelona Science Park, Ona Therapeutics develops new drugs aimed at blocking metastasis-forming cells. This therapeutic approach could prevent the formation of metastases and eliminate existing ones, potentially in any type of cancer.